Informatie:
Fout:
ID
34555
Beschrijving
A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01251120
Link
https://clinicaltrials.gov/show/NCT01251120
Trefwoorden
Versies (1)
- 19-01-19 19-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
19 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Rheumatoid Arthritis NCT01251120
Eligibility Rheumatoid Arthritis NCT01251120
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT01251120
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
adult patients, over the age of 18 years
boolean
ID.2
Item
diagnosis of moderate-to-severe active early rheumatoid arthritis (ra) of less than 2 years duration
boolean
ID.3
Item
das28 >3.2
boolean
ID.4
Item
swollen joint count (sjc) >/=6 (66 joint count), and tender joint count (tjc) >/=6 (68 joint count)
boolean
ID.5
Item
patients who have received dmards (including methotrexate) for 3-7 months
boolean
ID.6
Item
major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline
boolean
ID.7
Item
rheumatic autoimmune disease other than rheumatoid arthritis (secondary sjögrens syndrome or nodulosis with ra is permitted)
boolean
ID.8
Item
functional class iii or iv as defined by acr classification of functional status in rheumatoid arthritis
boolean
ID.9
Item
prior history of or current inflammatory joint disease other than ra
boolean